About agenus - AGEN
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
AGEN At a Glance
Agenus, Inc.
3 Forbes Road
Lexington, Massachusetts 02421-7305
| Phone | 1-781-674-4400 | Revenue | 114.20M | |
| Industry | Biotechnology | Net Income | 115.00K | |
| Sector | Health Technology | 2025 Sales Growth | 10.374% | |
| Fiscal Year-end | 12 / 2026 | Employees | 81 | |
| View SEC Filings |
AGEN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.818 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -39.643 |
| Enterprise Value to Sales | 3.665 |
| Total Debt to Enterprise Value | 0.80 |
AGEN Efficiency
| Revenue/Employee | 1,409,827.16 |
| Income Per Employee | 1,419.753 |
| Receivables Turnover | 16.29 |
| Total Asset Turnover | 0.504 |
AGEN Liquidity
| Current Ratio | 0.412 |
| Quick Ratio | 0.412 |
| Cash Ratio | 0.009 |
AGEN Profitability
| Gross Margin | 90.349 |
| Operating Margin | -18.001 |
| Pretax Margin | -2.70 |
| Net Margin | 0.101 |
| Return on Assets | 0.051 |
| Return on Equity | N/A |
| Return on Total Capital | 0.18 |
| Return on Invested Capital | N/A |
AGEN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 525.019 |
| Total Debt to Total Assets | 147.664 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 281.848 |